primari
biliari
cirrhosi
pbc
rare
autoimmun
liver
diseas
predominantli
affect
women
character
immun
destruct
intrahepat
bile
duct
aberr
express
mitochondri
antigen
biliari
epithelium
develop
antimitochondri
antibodi
ama
progress
loss
bile
duct
lead
accumul
bile
liver
fibrosi
cirrhosi
unrespons
therapi
licens
treatment
pbc
ursodeoxychol
acid
udca
therapi
act
choleret
agent
elimin
bile
liver
howev
third
patient
still
develop
progress
diseas
result
pbc
account
patient
requir
liver
transplant
develop
countri
apart
studi
udca
clinic
trial
pbc
mainli
gear
toward
investig
immunosuppress
agent
immunosuppress
proven
life
save
patient
autoimmun
hepat
aih
howev
outcom
similar
clinic
studi
pbc
disappoint
individu
treatment
littl
impact
halt
progress
pbc
specif
immunosuppress
agent
therefor
adopt
toxic
lack
efficaci
interest
cyclosporin
csa
one
drug
shown
evid
reduc
liver
relat
mortal
howev
csa
use
nontranspl
patient
due
advers
effect
renal
function
blood
pressur
even
though
immunosuppress
littl
role
manag
pbc
overlap
syndrom
pbc
aih
recogn
occur
patient
manifest
featur
diseas
immunosuppress
may
valu
diseas
manag
biochem
hepat
compon
disord
control
somewhat
corticosteroid
therapi
effect
systemat
studi
control
trial
treatment
choic
patient
liver
failur
secondari
pbc
liver
transplant
even
though
diseas
may
reoccur
outcom
usual
favor
two
third
patient
develop
ama
pbc
specif
phenotyp
bile
duct
aberr
express
mitochondri
mitochondri
phenotyp
howev
proport
patient
develop
biochem
histolog
diseas
frequenc
recurr
pbc
usual
increas
progress
time
histolog
diseas
report
patient
year
liver
transplant
anoth
consist
observ
mani
transplant
program
potent
immunosuppress
regimen
use
tacrolimu
acceler
onset
sever
recurr
diseas
contrast
csa
base
regimen
link
diminish
incid
recurr
diseas
exampl
found
probabl
recurr
pbc
year
patient
tacrolimu
compar
patient
csa
cohort
thousand
transplant
recipi
figur
also
found
primari
immunosuppress
csa
compar
tacrolimu
associ
eightfold
reduct
risk
pbc
recurr
agreement
liver
transplant
center
immunosuppress
regimen
use
probabl
contribut
era
effect
pbc
patient
undergo
liver
transplant
experienc
lower
incid
diseas
recurr
other
liver
transplant
center
report
similar
protect
era
effect
link
sever
factor
includ
specif
immunosuppress
regimen
use
younger
donor
decreas
cold
ischem
time
nevertheless
major
conclus
seri
document
outcom
patient
pbc
follow
liver
transplant
csa
associ
lower
incid
recurr
diseas
also
interest
primari
use
csa
shown
confer
protect
effect
autoimmun
diseas
de
novo
aih
liver
transplant
recipi
gener
well
decreas
risk
recurr
de
novo
inflammatori
bowel
diseas
liver
transplant
primari
scleros
cholang
psc
aih
heterogen
disord
observ
pediatr
adult
popul
variabl
present
prognosi
diagnosi
usual
establish
exclus
caus
liver
diseas
liver
histolog
presenc
varieti
autoantibodi
also
includ
spectrum
aih
poorli
understood
overlap
syndrom
pbc
psc
howev
overlap
syndrom
consid
contenti
pbc
psc
exclus
criteria
make
diagnosi
aih
de
novo
aih
recogn
decad
condit
affect
patient
transplant
hepat
disord
aih
compar
classic
aih
diagnosi
de
novo
aih
essenti
base
presenc
autoantibodi
distinct
histolog
find
exclus
condit
viral
hepat
acut
chronic
reject
immun
mediat
biliari
diseas
similar
diagnosi
aih
gener
popul
acknowledg
diagnosi
de
novo
aih
follow
liver
transplant
clearcut
lack
evidencebas
diagnost
criteria
distinguish
differ
entiti
strong
similar
de
novo
aih
recurr
aih
liver
transplant
recipi
classic
aih
nontranspl
set
studi
base
center
found
probabl
de
novo
aih
approxim
year
overal
incid
case
per
patientyear
notabl
frequenc
de
novo
aih
may
higher
preval
aih
gener
popul
probabl
transplant
patient
expos
potenti
risk
factor
regard
immunosuppress
usag
liver
transplant
recipi
maintain
csa
lower
risk
de
novo
aih
wherea
receiv
tacrolimu
mycophenol
mofetil
higher
risk
de
novo
aih
respect
figur
intriguingli
found
patient
donor
age
year
older
femal
donor
higher
risk
develop
de
novo
aih
respect
moreov
femal
recipi
gender
mismatch
protect
de
novo
aih
reduc
risk
word
younger
male
donor
primari
use
csa
protect
develop
de
novo
aih
similar
patient
pbc
immunosuppress
regimen
use
probabl
contribut
cohort
effect
observ
studi
patient
undergo
liver
transplant
period
experienc
lower
risk
de
novo
aih
compar
patient
transplant
decad
follow
argu
protect
effect
csa
could
also
attribut
concomit
use
steroid
previou
studi
shown
role
steroid
use
prevent
develop
de
novo
aih
genet
environment
factor
trigger
pbc
poorli
understood
one
could
argu
mechan
like
mediat
recurr
diseas
allograft
strong
herit
compon
diseas
difficult
quantifi
risk
develop
pbc
famili
member
rang
pbc
preval
monozygot
compar
dizygot
twin
sever
case
control
genom
wide
associ
studi
link
pbc
hla
dr
dq
class
ii
region
cytokin
axi
gene
associ
host
pathogen
interact
collect
suscept
data
suggest
hypothesi
patient
pbc
global
disturb
sens
respons
environment
agent
tempt
specul
therefor
penetr
recurr
diseas
mayb
relat
part
acquisit
protect
allel
new
allograft
prevent
establish
infecti
process
data
lack
support
conjectur
recurr
pbc
follow
transplant
strongli
suggest
infecti
process
epidemiolog
data
suggest
transmiss
etiolog
well
spous
unrel
famili
member
even
care
provid
report
develop
pbc
suggest
role
environment
factor
diseas
also
pbc
report
cluster
specif
geograph
region
migrat
studi
show
children
develop
rel
incid
adopt
host
countri
wherea
parent
regard
environment
agent
xenobiot
specif
bacteria
betaretroviru
link
develop
pbc
none
confirm
caus
diseas
date
group
first
character
human
betaretroviru
resembl
mous
mammari
tumor
viru
mmtv
patient
pbc
nearli
ten
year
ago
initi
find
import
betaretroviru
shown
trigger
mitochondri
phenotyp
pbc
vitro
found
cell
display
mitochondri
phenotyp
vivo
patient
pbc
evid
hbrv
perihepat
lymph
node
viru
difficult
detect
liver
question
rais
concern
valid
origin
find
accordingli
studi
ongo
demonstr
provir
integr
patient
liver
diseas
provid
substanti
evid
hbrv
potenti
human
pathogen
understood
multipl
layer
proof
requir
link
hbrv
pathogenesi
pbc
sever
interrel
ongo
studi
aim
address
issu
demonstr
provir
integr
bile
duct
patient
pbc
elisa
construct
determin
seropreval
hbrv
infect
larg
cohort
patient
liver
diseas
also
mous
model
use
demonstr
infect
close
relat
mmtv
trigger
autoimmun
biliari
diseas
anim
model
use
valid
combin
antivir
treatment
inhibit
betaretroviru
infect
ongo
clinic
trial
investig
whether
antiretrovir
therapi
improv
histolog
biochem
clinic
endpoint
patient
pbc
accordingli
work
model
betaretroviru
may
trigger
viral
cholang
suscept
individu
specif
hla
dr
dq
class
ii
allel
genet
polymorph
associ
cytokin
axi
similar
model
could
use
propos
factor
trigger
origin
diseas
also
persist
allograft
two
third
patient
develop
ama
mitochondri
phenotyp
bile
duct
one
third
patient
develop
biochem
histolog
diseas
recurr
year
follow
transplant
data
suggest
approxim
one
third
patient
pbc
receiv
liver
transplant
protect
recurr
diseas
evid
support
hypothesi
environment
trigger
may
persist
two
third
patient
wherea
third
develop
progress
diseas
whether
factor
modul
diseas
recurr
protect
polymorph
involv
hla
allel
allograft
use
younger
donor
shorter
cold
ischem
time
remain
resolv
howev
major
factor
reproduc
shown
protect
junctur
primari
use
csa
littl
known
etiolog
pathogenesi
aih
nontranspl
set
develop
de
novo
aih
remain
total
mysteri
inde
three
divers
process
could
involv
pathogenesi
de
novo
aih
includ
autoimmun
form
frust
allograft
reject
possibl
viral
infect
fact
suggest
aih
may
repres
serolog
unidentifi
viral
infect
found
evid
hbrv
infect
patient
aih
one
case
acut
onset
aih
viral
load
highest
acut
present
diminish
corticosteroid
treatment
observ
lead
propos
model
use
corticosteroid
may
dual
purpos
limit
viral
spread
diminish
inflamm
inde
relat
agent
mmtv
oblig
prerequisit
replic
divid
lymphocyt
set
liver
transplant
model
would
also
consist
antivir
antilymphocyt
activ
csa
protect
develop
de
novo
aih
observ
potent
immunosuppress
tacrolimu
associ
earlier
sever
recurr
pbc
suggest
two
potenti
compat
hypothes
first
tacrolimu
inhibit
immun
system
greater
degre
permit
emerg
infecti
agent
second
csa
may
act
part
antivir
patient
pbc
follow
liver
transplant
acknowledg
howev
data
demonstr
recurr
hbrv
allograft
lack
support
hypothes
nevertheless
found
csa
analogu
inhibit
betaretroviru
product
suggest
critic
role
cyclophilin
replic
infect
betaretrovirus
vitro
studi
use
mous
breast
cancer
cell
contain
integr
mmtv
proviru
test
sensit
antivir
immunosuppress
agent
diminish
mmtv
product
design
model
use
test
earli
event
retroviru
life
cycl
viral
intern
uncoat
disassembl
revers
transcript
nuclear
import
preintegr
complex
provir
integr
figur
nevertheless
downstream
product
infecti
particl
integr
proviru
studi
vitro
studi
observ
reduct
revers
transcriptas
activ
viral
genom
level
supernat
cell
incub
cyclophilin
inhibitor
csa
wherea
tacrolimu
revers
transcriptas
inhibitor
significantli
less
effect
steadi
state
viral
protein
level
unaffect
presenc
csa
howev
observ
chang
proteas
process
mmtv
gag
protein
either
csa
wherea
combin
hiv
proteas
inhibitor
lopinavir
ritonavir
kaletratm
partial
inhibit
product
mmtv
capsid
protein
clear
howev
like
block
viral
replic
independ
immunosuppress
natur
csa
incub
result
similar
level
revers
transcriptas
genom
equival
point
howev
mechan
either
csa
block
viral
product
yet
resolv
review
betaretrovir
life
cycl
help
us
understand
critic
step
csa
may
interfer
viral
replic
figur
discuss
use
cell
stabli
integr
mmtv
proviru
prevent
studi
earli
event
infect
nevertheless
cyclophilin
antagonist
may
function
prevent
intern
virion
observ
sever
agent
includ
human
papilloma
viru
hpv
measl
viru
hiv
exampl
csa
counteract
cyclophilin
b
enabl
necessari
conform
chang
hpv
minor
capsid
protein
requir
viral
intern
also
known
cyclophilin
cyclophilin
b
assist
cellular
entri
hiv
measl
viru
respect
critic
interact
transmembran
glycoprotein
belong
immunoglobulin
superfamili
howev
one
demonstr
date
csa
analogu
specif
function
block
mediat
viral
entri
cyclophilin
also
play
import
role
viral
uncoat
disassembl
hpv
process
occur
endosom
compart
assist
cyclophilin
b
exampl
activ
inhibit
csa
anoth
exampl
cyclophilin
mediat
viral
replic
includ
disassembl
matur
core
nuclear
import
hiv
preintegr
complex
figur
cyclophilin
play
critic
role
assist
interact
viral
capsid
protein
major
cytoplasm
compon
nuclear
pore
complex
necessari
uncoat
capsid
shuttl
preintegr
complex
nucleu
case
inhibit
cyclophilin
interact
hiv
capsid
csa
impair
passag
matur
viral
core
nuclear
pore
complex
follow
provir
integr
cyclophilin
shown
play
role
sever
process
viral
life
cycl
compris
viral
rna
protein
product
assembl
matur
figur
exampl
csa
shown
block
activ
hiv
enhanc
region
inhibit
viral
rna
transcript
agent
hepat
c
viru
hcv
reli
cyclophilin
interact
viral
compon
replic
complex
produc
rna
transcript
process
also
block
csa
similar
vein
csa
block
coronaviru
replic
via
unknown
mechan
step
prior
rna
protein
synthesi
signific
anecdot
evid
favor
inhibit
rna
transcript
presenc
csa
tacrolimu
potenti
rather
block
transcript
activ
mmtv
promot
howev
process
modul
dexamethason
activ
glucocorticoid
respons
element
long
termin
repeat
also
possibl
cyclophilin
inhibitor
neg
regul
viral
protein
steadi
state
level
one
mani
step
involv
viral
protein
product
turnov
exampl
csa
block
nuclear
export
influenza
rna
transcript
furthermor
process
hcv
polyprotein
function
compon
requir
support
cyclophilin
interact
block
csa
presenc
csa
also
acceler
proteolyt
degrad
influenza
matrix
protein
augment
interact
cyclophilin
contrast
cyclophilin
inhibitor
trigger
loss
hiv
vpr
known
partner
cyclophilin
proteosom
activ
discuss
vitro
experi
mmtv
produc
cell
unlik
cyclophilin
inhibitor
impact
step
viral
entri
viral
transcript
protein
product
given
csa
treatment
impact
mmtv
rna
protein
level
cell
data
suggest
viral
transcript
protein
product
like
proce
appropri
produc
cell
therefor
addit
studi
direct
toward
investig
viral
assembl
matur
infect
stage
viral
life
cycl
numer
virus
util
cyclophilin
target
cell
infect
specif
know
hiv
incorpor
cyclophilin
bud
virion
interfer
process
csa
reduc
infect
data
suggest
model
virion
incorpor
cyclophilin
target
cell
cyclophilin
may
necessari
effect
intern
uncoat
andor
nuclear
import
mmtv
genom
present
patient
pbc
limit
option
therapeut
intervent
clearli
better
treatment
requir
patient
progress
liver
failur
treat
recurr
diseas
follow
liver
transplant
antiretrovir
therapi
pbc
shown
promis
improv
hepat
biochemistri
histolog
specif
drug
employ
clinic
trial
date
manufactur
treat
hiv
rather
hbrv
preliminari
data
support
hypothesi
csa
cyclophilin
inhibitor
may
inhibit
betaretroviru
activ
matur
infect
stage
target
cell
character
role
cyclophilin
betaretroviru
life
cycl
would
benefici
vitro
mous
model
pbc
mmtv
infect
studi
encourag
would
serv
dual
purpos
character
mechan
cyclophilin
inhibitor
block
hbrv
product
identifi
novel
manag
strategi
patient
pbc
